Fortress Biotech subsidiary Urica says Crystalys closes $130 million Series B financing
FBIO•Crystalys closes oversubscribed Series B
Fortress Biotech subsidiary Urica Therapeutics disclosed Crystalys Therapeutics closed an oversubscribed $130 million Series B financing.
The financing supports late-stage global development, regulatory work and commercialization planning for gout drug dotinurad, which is now in Phase 3 trials.
Urica retains minority stake and royalty rights
Urica holds a minority equity stake in Crystalys, following Crystalys’ 2024 acquisition of dotinurad from Urica.
Urica is eligible for a 3% royalty on future net sales of dotinurad.
